- Home
- SOPH vs LUNG Comparison
SOPH vs LUNG Comparison
Compare SOPH & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPH
- LUNG
- Stock Information
- Founded
- SOPH 2011
- LUNG 1995
- Country
- SOPH Switzerland
- LUNG United States
- Employees
- SOPH N/A
- LUNG N/A
- Industry
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- LUNG Industrial Specialties
- Sector
- SOPH Health Care
- LUNG Health Care
- Exchange
- SOPH Nasdaq
- LUNG Nasdaq
- Market Cap
- SOPH 247.0M
- LUNG 248.0M
- IPO Year
- SOPH 2021
- LUNG 2020
- Fundamental
- Price
- SOPH $3.42
- LUNG $6.89
- Analyst Decision
- SOPH Strong Buy
- LUNG Strong Buy
- Analyst Count
- SOPH 3
- LUNG 7
- Target Price
- SOPH $7.00
- LUNG $13.71
- AVG Volume (30 Days)
- SOPH 36.6K
- LUNG 240.7K
- Earning Date
- SOPH 11-05-2024
- LUNG 10-28-2024
- Dividend Yield
- SOPH N/A
- LUNG N/A
- EPS Growth
- SOPH N/A
- LUNG N/A
- EPS
- SOPH N/A
- LUNG N/A
- Revenue
- SOPH $64,938,000.00
- LUNG $76,583,000.00
- Revenue This Year
- SOPH $7.70
- LUNG $22.73
- Revenue Next Year
- SOPH $20.61
- LUNG $19.02
- P/E Ratio
- SOPH N/A
- LUNG N/A
- Revenue Growth
- SOPH 20.14
- LUNG 26.26
- 52 Week Low
- SOPH $2.55
- LUNG $5.46
- 52 Week High
- SOPH $7.37
- LUNG $14.84
- Technical
- Relative Strength Index (RSI)
- SOPH 41.95
- LUNG 37.93
- Support Level
- SOPH $3.03
- LUNG $6.91
- Resistance Level
- SOPH $3.50
- LUNG $7.47
- Average True Range (ATR)
- SOPH 0.25
- LUNG 0.35
- MACD
- SOPH -0.05
- LUNG -0.19
- Stochastic Oscillator
- SOPH 30.53
- LUNG 7.10
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.